{
    "nct_id": "NCT04700124",
    "official_title": "A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304)",
    "inclusion_criteria": "* Have a histologically confirmed diagnosis of urothelial carcinoma (UC) / muscle invasive bladder cancer (MIBC) (T2-T4aN0M0 or T1-T4aN1M0) with predominant (≥50%) urothelial histology.\n* Have clinically non-metastatic bladder cancer (N≤1 M0) determined by imaging (computed tomography (CT) or magnetic resonance imaging (MRI) of the chest/abdomen/pelvis\n* Be deemed eligible for Radical Cystectomy (RC) + Pelvic Lymph Node Dissection (PLND)\n* Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Have adequate organ function.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has a known additional malignancy that is progressing or has required active anti-cancer treatment ≤3 years of study randomization with certain exceptions\n* Has received any prior systemic treatment for MIBC or non-invasive muscle bladder cancer (NMIBC - prior treatment for NMIBC with intravesical BCG/chemotherapy is permitted) or prior therapy with an anti- programmed cell death 1 (PD-1), anti-programmed cell death ligand 1/ ligand 2 (PD-L1/L2), or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)\n* Has ≥N2 disease or metastatic disease (M1) as identified by imaging\n* Is cisplatin-ineligible, as defined by meeting any one of the cisplatin ineligibility criteria as per protocol\n* Has received prior systemic anticancer therapy including investigational agents within 3 years of randomization or any radiotherapy to the bladder\n* Has undergone partial cystectomy of the bladder to remove any NMIBC or MIBC\n* Has received a live or live attenuated vaccine within 30 days before the first dose of study intervention\n* Has a diagnosis of immunodeficiency or has a known history of human immunodeficiency virus (HIV) infection. Hepatitis B infection or known active Hepatitis C infection\n* Has a known psychiatric or substance abuse disorder\n* Has had an allogenic tissue/solid organ transplant\n* Has ongoing sensory or motor neuropathy Grade 2 or higher\n* Has active keratitis (superficial punctate keratitis) or corneal ulcerations\n* Has a history of uncontrolled diabetes defined as hemoglobin A1c (HbA1c) ≥8% or HbA1c 7% to <8% with associated diabetes symptoms",
    "miscellaneous_criteria": ""
}